An Exploratory Trial of Biomarkers for Panitumumab Response Among Previously Treated Patients With KRAS Wild Type Metastatic Colorectal Cancer.
Phase of Trial: Phase II
Latest Information Update: 04 Dec 2015
At a glance
- Drugs Panitumumab (Primary)
- Indications Colorectal cancer
- Focus Biomarker; Therapeutic Use
- 01 Dec 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 21 Feb 2013 Planned end date added to 1 May 2013 as reported by ClinicalTrials.gov.
- 02 Feb 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.